The AP-GELP Study: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Phosphodiesterase 4-Inhibitor Apremilast in Female Genital Erosive Lichen Planus
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Genital disorders; Lichen planus; Vaginal diseases; Vulval disorders
- Focus Therapeutic Use
- Acronyms AP-GELP
- 30 Aug 2019 Planned number of patients changed from 40 to 42.
- 30 Aug 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2020.
- 30 Aug 2019 Status changed from not yet recruiting to recruiting.